Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
about
Hedgehog signaling pathway and its targets for treatment in basal cell carcinomaSonic Hedgehog promotes tumor cell survival by inhibiting CDON pro-apoptotic activityItraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growthEvidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy.Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.PTHrP treatment fails to rescue bone defects caused by Hedgehog pathway inhibition in young micePharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse modelCombining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis.Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide inductionNovel investigational drugs for basal cell carcinoma.Cancer stem cells: a new framework for the design of tumor therapies.Hedgehog signaling pathway as a therapeutic target in various types of cancer.Mechanisms of Hedgehog signalling in cancer.Review: personalized mice: modelling the molecular heterogeneity of medulloblastoma.The utility of hedgehog signaling pathway inhibition for cancer.The sonic hedgehog-GLI1 signaling pathway in brain tumor development.Hedgehog pathway inhibitors: a patent review (2009--present).Hedgehog inhibitors: a patent review (2013 - present).Synthesis and cytotoxicity studies of Hedgehog enzyme inhibitors SANT-1 and GANT-61 as anticancer agents.TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.Discovery of NVP-LDE225, a Potent and Selective Smoothened AntagonistThe Hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer.Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma.Synthesis and Smo Activity of Some Novel Benzamide Derivatives.Hedgehog signalling pathway inhibitors as cancer suppressing agents
P2860
Q27021460-E386A200-AEA1-49DE-BBBF-7D6993439C2CQ27317023-B97AE497-12E7-436F-B037-F75B0FBF81E1Q28279473-3DE87A91-071E-4508-9500-F041A06C7D3BQ33829820-C36616B4-EB48-4D95-B10B-FB08E6BB8B66Q35868567-2BE66920-4D9B-4C55-ADEE-C31BE8C87DB9Q35944343-2A858C03-E808-4CB9-BA8A-99C5A1F971FAQ36207322-110B42CB-E960-4E9F-9760-786C2A4516FDQ36408686-3EEB9F82-5CF9-4300-8451-B459547589C4Q36622772-F4F84F48-1E3C-4FC2-87D0-DC71CFD34C45Q36719636-7EF9B21F-D1A8-438A-9748-E399DE29DF3FQ36926998-8C325D03-3BF3-4DE9-8D9D-635E7BC14D14Q37005492-7CE4E048-0E13-475B-AB32-25369C9C10C5Q37775962-8C5EF3E4-8090-4161-B107-8909B4E4CD0CQ37796629-37B50841-213C-4250-911C-965E5714A8B5Q37890489-83EFD388-1B57-430C-88AA-3C84FB878745Q37923514-D7E9677C-6F7B-4BD8-A407-4073440C1CEBQ37954412-834B4B85-3B96-4DA9-B470-C7AF618D0064Q38031211-38AD3520-4750-426A-9095-A2D35EF70F4CQ38044769-7AB55817-32CB-487D-B4AA-A8B43C11565BQ38072095-A955731B-C169-4621-8161-C67F334C3055Q38366266-B697D55B-E841-4B87-A174-50AEAEAEB111Q39024542-0DB651FA-9012-45B8-ABA7-F55A303A645CQ39092314-2D44A437-E65D-447B-8F0B-1125B124539FQ39151730-63F54A4D-C689-4604-892C-6D7F34588A73Q39165138-DE360020-422C-42E4-AF01-C4E1B6137DA9Q39367534-EDE7BFDE-1B59-4173-97D8-2216A7B93DB8Q42282551-3C5664E6-8F8A-4592-A69A-39D158FED22CQ47320107-7CE81C52-1EAA-4D43-858B-657C5ED8DCCEQ48308959-1A80941A-F6A0-4CF9-909D-A0D30FC793ACQ57905193-57D4072C-37E1-4AD7-8788-4D9EBB32E50C
P2860
Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
@ast
Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
@en
type
label
Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
@ast
Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
@en
prefLabel
Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
@ast
Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
@en
P2093
P2860
P1476
Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.
@en
P2093
Alfredo C Castro
Martin R Tremblay
Michael Nesler
Robin Weatherhead
P2860
P304
P356
10.1517/13543770903008551
P407
P577
2009-08-01T00:00:00Z